666 related articles for article (PubMed ID: 28193515)
1. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.
Hyams JS; Dubinsky MC; Baldassano RN; Colletti RB; Cucchiara S; Escher J; Faubion W; Fell J; Gold BD; Griffiths A; Koletzko S; Kugathasan S; Markowitz J; Ruemmele FM; Veereman G; Winter H; Masel N; Shin CR; Tang KL; Thayu M
Gastroenterology; 2017 Jun; 152(8):1901-1914.e3. PubMed ID: 28193515
[TBL] [Abstract][Full Text] [Related]
2. Primary sclerosing cholangitis associated with inflammatory bowel disease: an observational study in a Southern Europe population focusing on new therapeutic options.
Franceschet I; Cazzagon N; Del Ross T; D'Incà R; Buja A; Floreani A
Eur J Gastroenterol Hepatol; 2016 May; 28(5):508-13. PubMed ID: 26872110
[TBL] [Abstract][Full Text] [Related]
3. Hemophagocytic Lymphohistiocytosis Occurring in Inflammatory Bowel Disease: Systematic Review.
Coburn ES; Siegel CA; Winter M; Shah ED
Dig Dis Sci; 2021 Mar; 66(3):843-854. PubMed ID: 32300936
[TBL] [Abstract][Full Text] [Related]
4. Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
Cheddani H; Dauchet L; Fumery M; Charpentier C; Marie Bouvier A; Dupas JL; Pariente B; Peyrin-Biroulet L; Savoye G; Gower-Rousseau C
Am J Gastroenterol; 2016 Oct; 111(10):1428-1436. PubMed ID: 27481308
[TBL] [Abstract][Full Text] [Related]
5. Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden.
Everhov ÅH; Halfvarson J; Myrelid P; Sachs MC; Nordenvall C; Söderling J; Ekbom A; Neovius M; Ludvigsson JF; Askling J; Olén O
Gastroenterology; 2018 Feb; 154(3):518-528.e15. PubMed ID: 29102619
[TBL] [Abstract][Full Text] [Related]
6. Biologic Agents Are Associated with Excessive Weight Gain in Children with Inflammatory Bowel Disease.
Haas L; Chevalier R; Major BT; Enders F; Kumar S; Tung J
Dig Dis Sci; 2017 Nov; 62(11):3110-3116. PubMed ID: 28895012
[TBL] [Abstract][Full Text] [Related]
7. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
Holmstrøm RB; Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
Dig Dis Sci; 2018 Jun; 63(6):1583-1591. PubMed ID: 29564674
[TBL] [Abstract][Full Text] [Related]
8. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.
Kim ES; Song GA; Cho KB; Park KS; Kim KO; Jang BI; Kim EY; Jeon SW; Lee HS; Yang CH; Lee YK; Lee DW; Kim SK; Kim TO; Lee J; Kim HW; Jee SR; Park SJ; Kim HJ
World J Gastroenterol; 2015 Mar; 21(11):3308-16. PubMed ID: 25805938
[TBL] [Abstract][Full Text] [Related]
9. An Increased Serum N-Terminal Telopeptide of Type I Collagen, a Biochemical Marker of Increased Bone Resorption, Is Associated with Infliximab Therapy in Patients with Crohn's Disease.
Sugimoto K; Ikeya K; Iida T; Kawasaki S; Arai O; Umehara K; Watanabe F; Tani S; Oishi S; Osawa S; Yamamoto T; Hanai H
Dig Dis Sci; 2016 Jan; 61(1):99-106. PubMed ID: 26254083
[TBL] [Abstract][Full Text] [Related]
10. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease.
Renna S; Cottone M; Orlando A
World J Gastroenterol; 2014 Aug; 20(29):9675-90. PubMed ID: 25110407
[TBL] [Abstract][Full Text] [Related]
11. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab.
Thiebault H; Boyard-Lasselin P; Guignant C; Guillaume N; Wacrenier A; Sabbagh C; Rebibo L; Brazier F; Meynier J; Nguyen-Khac E; Dupas JL; Goëb V; Fumery M
Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):876-81. PubMed ID: 27101404
[TBL] [Abstract][Full Text] [Related]
12. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
[TBL] [Abstract][Full Text] [Related]
13. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.
Weismüller TJ; Trivedi PJ; Bergquist A; Imam M; Lenzen H; Ponsioen CY; Holm K; Gotthardt D; Färkkilä MA; Marschall HU; Thorburn D; Weersma RK; Fevery J; Mueller T; Chazouillères O; Schulze K; Lazaridis KN; Almer S; Pereira SP; Levy C; Mason A; Naess S; Bowlus CL; Floreani A; Halilbasic E; Yimam KK; Milkiewicz P; Beuers U; Huynh DK; Pares A; Manser CN; Dalekos GN; Eksteen B; Invernizzi P; Berg CP; Kirchner GI; Sarrazin C; Zimmer V; Fabris L; Braun F; Marzioni M; Juran BD; Said K; Rupp C; Jokelainen K; Benito de Valle M; Saffioti F; Cheung A; Trauner M; Schramm C; Chapman RW; Karlsen TH; Schrumpf E; Strassburg CP; Manns MP; Lindor KD; Hirschfield GM; Hansen BE; Boberg KM;
Gastroenterology; 2017 Jun; 152(8):1975-1984.e8. PubMed ID: 28274849
[TBL] [Abstract][Full Text] [Related]
14. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease.
Osterman MT; Sandborn WJ; Colombel JF; Robinson AM; Lau W; Huang B; Pollack PF; Thakkar RB; Lewis JD
Gastroenterology; 2014 Apr; 146(4):941-9. PubMed ID: 24361468
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of biologics in pediatric inflammatory boweldisease: Real-life data from the Sicilian Network.
Romeo AC; Ventimiglia M; Dipasquale V; Orlando A; Citrano M; Pellegrino S; Accomando S; Cottone M; Romano C
Clin Res Hepatol Gastroenterol; 2020 Apr; 44(2):223-229. PubMed ID: 31204314
[TBL] [Abstract][Full Text] [Related]
16. Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease.
Androulakis I; Zavos C; Christopoulos P; Mastorakos G; Gazouli M
World J Gastroenterol; 2015 Dec; 21(47):13205-11. PubMed ID: 26715803
[TBL] [Abstract][Full Text] [Related]
17. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry.
Lichtenstein GR; Feagan BG; Cohen RD; Salzberg BA; Diamond RH; Langholff W; Londhe A; Sandborn WJ
Am J Gastroenterol; 2014 Feb; 109(2):212-23. PubMed ID: 24394749
[TBL] [Abstract][Full Text] [Related]
18. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.
Nobile S; Gionchetti P; Rizzello F; Calabrese C; Campieri M
Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):458-65. PubMed ID: 24445727
[TBL] [Abstract][Full Text] [Related]
19. Treatment with infliximab for pediatric Crohn's disease: Nationwide survey of Japan.
Hosoi K; Ohtsuka Y; Fujii T; Kudo T; Matsunaga N; Tomomasa T; Tajiri H; Kunisaki R; Ishige T; Yamada H; Arai K; Yoden A; Ushijima K; Aomatsu T; Nagata S; Uchida K; Takeuchi K; Shimizu T
J Gastroenterol Hepatol; 2017 Jan; 32(1):114-119. PubMed ID: 27478130
[TBL] [Abstract][Full Text] [Related]
20. Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease.
George LA; Gadani A; Cross RK; Jambaulikar G; Ghazi LJ
Dig Dis Sci; 2015 Nov; 60(11):3424-30. PubMed ID: 26115749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
